

Domainex is a multi-award winning, fully integrated drug discovery medicines research services partner. The company provides innovative and customized biology and chemistry services to advance the disease research projects of its clients, from target expression to pre-clinical candidate nomination. Domainex works closely and collaboratively with its partners to understand their aspirations and requirements. It leverages its considerable knowledge of drug discovery to provide intellectual input, creativity, and innovation to maximize the chances of a successful outcome.

Domainex constantly demonstrates itself as the drug discovery services provider of choice.

Awards Success

Earlier this year, Domainex was honored to announce it received a King's Award for Enterprise: International Trade 2023. The prestigious award recognized the company's outstanding growth in international trade over three years which amounted to a more than one hundred per cent increase in international revenues during the period.

Domainex also recently won a Business Weekly award in the category of Life Sciences Scale-Up. The company has been shortlisted for several other awards including:

- OBN Awards (in the categories of Most Impactful CRO and Most Impactful Industry Collaboration while Domainex's Head of Chemistry, Dr Andrew Ratcliffe, is up for the Special Recognition Award)
- Cambridgeshire SME Business Awards (in the categories of Business of the Year More than 50 Employees, Employer of the Year and High Growth Business of the Year)
- Scrip Awards (in the category of Business Development Team of the Year)
- Growing Business Awards 2023 (in the categories of Employer of the Year, The Bridges Positive Impact Award and Growing Business of the Year: Turnover £10m-£15m)

More awards announcements are therefore expected from Domainex later this year.



New Technologies

Domainex is constantly researching new technologies and approaches to drug discovery to ensure it can offer the best possible service to its customers. Earlier this year, the company launched its new [Cryogenic Electron Microscopy \(Cryo-EM\)](#) service, further expanding its structural biology offering. It has also launched other new services such as [flow cytometry](#) and [Isothermal Titration Calorimetry](#)

[\(ITC\)](#) expanding its assay biology capabilities. Additionally, new service launches are expected to be announced later this year.



Expanding Research Operations

Domainex is growing at pace with record revenues achieved over the last two years. The company is now recognized as one of the UK's foremost providers of drug discovery services and has ambitious plans to double its revenue over the next three years, necessitating further expansion of its facilities. In July of this year, Domainex announced it had secured a lease for a new, fully fitted, three-story building. At over 24,000 sq ft, this new building will provide a significantly increased floor area for Domainex's biology department allowing space for both new instrumentation and staff. Domainex is anticipated to take occupation by the end of the year. With its existing Chemistry and Bioanalytical Centre of Excellence at Chesterford Research Park, the combined footprint of Domainex research facilities will exceed 44,000 sq ft.



If you are interested in exploring what Domainex can do for your company, please reach out to Michael Callahan, PhD, Senior Trade and Investment Officer at the British Consulate, Boston michael.callahan@businessandtrade.gov.uk.

Domainex will be visiting the Boston area during the week of 25th September and would be delighted to meet with you.